Research Evidence and Clinical Trial Data
Landmark Clinical Studies
The clinical development of sildenafil citrate involved extensive research programmes spanning multiple years. Initial pivotal trials demonstrated significant improvements in erectile function compared to placebo groups. These studies, conducted across diverse patient populations, established the foundation for regulatory approval in the UK and internationally.
Efficacy Outcomes from Research
Clinical trials consistently report success rates of 70-80% for men taking sildenafil for erectile dysfunction. The International Index of Erectile Function (IIEF) questionnaire, used in most studies, showed statistically significant improvements across all domains of sexual function. Research indicates that effectiveness may vary based on underlying causes of ED, with higher success rates observed in men with psychogenic compared to organic causes.
Safety Profile from Clinical Data
Long-term safety studies have followed patients for several years, providing comprehensive data on adverse effects and cardiovascular safety. The most commonly reported side effects in clinical trials include headache (occurring in approximately 15% of participants), facial flushing (10%), and nasal congestion (4%). Most adverse effects were mild to moderate in severity and temporary in nature.
Dosing Research and Optimisation
Clinical trials evaluated various dosing regimens, leading to current recommendations of 25mg, 50mg, and 100mg strengths. Research demonstrates that 50mg represents an appropriate starting dose for most men, with the option to adjust based on individual response and tolerability. Studies show that taking sildenafil on an empty stomach may improve onset time, whilst fatty meals can delay absorption.
Cardiovascular Safety Studies
Extensive cardiovascular research has been conducted given the mechanism of action of PDE5 inhibitors. Clinical data indicates that sildenafil may cause mild, temporary reductions in blood pressure. However, in men with stable cardiovascular disease, research suggests the medication can be used safely under medical supervision. The contraindication with nitrates is absolute, based on research showing potentially dangerous blood pressure drops.
Generic vs Branded Formulations
Bioequivalence studies demonstrate that generic sildenafil contains the same active ingredient as branded Viagra and produces equivalent therapeutic effects. Research confirms that both formulations have identical pharmacokinetic profiles, meaning they are absorbed and metabolised in the same manner. At EverydayMeds, patients can choose between branded Viagra or generic sildenafil during the consultation process, both requiring the same clinical assessment and prescription requirements.
